drugset
Drugs / anti-IgE
last change Dec 2025 re-read 3 minutes ago

anti-IgE

also known as Xolair
Developed for
allergic disease
Investigated by
Medical University of Vienna

Trials 1

today NCT03019237 · not/applicable
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
— NCT03019237 Nov 2012 → May 2013 allergic disease Medical University of Vienna Completed No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2025-12-03 Celltrion Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR® celltrion.com ↗
2025-03-10 Celltrion U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR® celltrion.com ↗
2024-02-25 Hoffmann-La Roche New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies roche.com ↗
2024-02-25 Genentech, Inc. New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies gene.com ↗
2020-01-09 Novartis Pharmaceuticals Novartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria novartis.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as anti-IgE ClinicalTrials.gov intervention name — accepted as the source's own label NCT03019237 ↗
Known as Xolair “Anti-IgE (Xolair) will be freshly diluted in sterile 0.9% sodium chloride solution (438 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both...” NCT03019237 ↗
Route Intranasal “intranasal anti-IgE” NCT03019237 ↗